264 related articles for article (PubMed ID: 36215167)
21. Oral HIF-2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.
Wiley HE; Srinivasan R; Maranchie JK; Chhablani J; Bøndergaard Iversen AB; Kruse A; Jonasch E; Gombos DS; Else T; Demirci H; Maughan BL; Hartnett ME; Coleman HR; Fu W; Perini RF; Liu Y; Linehan WM; Chew EY;
Ophthalmology; 2024 Jun; ():. PubMed ID: 38849055
[TBL] [Abstract][Full Text] [Related]
22. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
Curry L; Soleimani M
Future Oncol; 2024 Apr; ():1-16. PubMed ID: 38639572
[TBL] [Abstract][Full Text] [Related]
23. Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease.
Faiyaz-Ul-Haque M; Jamil M; Aslam M; Abalkhail H; Al-Dayel F; Basit S; Nawaz Z; Zaidi SHE
Cancer Genet; 2020 May; 243():1-6. PubMed ID: 32179488
[TBL] [Abstract][Full Text] [Related]
24. Von hippel-lindau disease: a genetic and clinical review.
Haddad NM; Cavallerano JD; Silva PS
Semin Ophthalmol; 2013; 28(5-6):377-86. PubMed ID: 24138046
[TBL] [Abstract][Full Text] [Related]
25. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
26. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract][Full Text] [Related]
27. von Hippel-Lindau disease-related neoplasia with an emphasis on renal manifestations.
Tekin B; Erickson LA; Gupta S
Semin Diagn Pathol; 2024 Jan; 41(1):20-27. PubMed ID: 37980175
[TBL] [Abstract][Full Text] [Related]
28. Von Hippel-Lindau disease (VHL): a need for a murine model with retinal hemangioblastoma.
Park S; Chan CC
Histol Histopathol; 2012 Aug; 27(8):975-84. PubMed ID: 22763871
[TBL] [Abstract][Full Text] [Related]
29. Whole-exome sequencing and immunohistochemistry findings in von Hippel-Lindau disease.
Guo X; Gao L; Hong X; Guo D; Di W; Wang X; Xu Z; Xing B
Mol Genet Genomic Med; 2019 Sep; 7(9):e880. PubMed ID: 31317677
[TBL] [Abstract][Full Text] [Related]
30. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment.
Klingler JH; Gläsker S; Bausch B; Urbach H; Krauss T; Jilg CA; Steiert C; Puzik A; Neumann-Haefelin E; Kotsis F; Agostini H; Neumann HPH; Beck J
Childs Nerv Syst; 2020 Oct; 36(10):2537-2552. PubMed ID: 32507909
[TBL] [Abstract][Full Text] [Related]
31. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
[TBL] [Abstract][Full Text] [Related]
32. Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.
Chan CC; Collins AB; Chew EY
Retina; 2007 Jan; 27(1):1-7. PubMed ID: 17218907
[TBL] [Abstract][Full Text] [Related]
33. Genotype-phenotype analysis of von Hippel-Lindau syndrome in Korean families: HIF-α binding site missense mutations elevate age-specific risk for CNS hemangioblastoma.
Lee JS; Lee JH; Lee KE; Kim JH; Hong JM; Ra EK; Seo SH; Lee SJ; Kim MJ; Park SS; Seong MW
BMC Med Genet; 2016 Jul; 17(1):48. PubMed ID: 27439424
[TBL] [Abstract][Full Text] [Related]
34. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
[TBL] [Abstract][Full Text] [Related]
35. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
Choi WW; Boland JL; Kalola A; Lin J
Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
[TBL] [Abstract][Full Text] [Related]
36. Von Hippel-Lindau syndrome. A pleomorphic condition.
Friedrich CA
Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173
[TBL] [Abstract][Full Text] [Related]
37. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system.
Gläsker S; Bender BU; Apel TW; Natt E; van Velthoven V; Scheremet R; Zentner J; Neumann HP
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):758-62. PubMed ID: 10567493
[TBL] [Abstract][Full Text] [Related]
38. VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects.
Aronow ME; Wiley HE; Gaudric A; Krivosic V; Gorin MB; Shields CL; Shields JA; Jonasch EW; Singh AD; Chew EY
Retina; 2019 Dec; 39(12):2243-2253. PubMed ID: 31095066
[TBL] [Abstract][Full Text] [Related]
39. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
40. An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma.
Muscarella LA; Barbano R; Augello B; Formica V; Micale L; Zelante L; D'Agruma L; Merla G
J Hum Genet; 2007; 52(6):485-491. PubMed ID: 17437055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
